Drug Profile
Research programme: vascular endothelial growth factor receptor 3 inhibitors - Bionomics/Cancer Therapeutics CRC
Alternative Names: BL 011256; BNC 420; CTx 0357927; CTx-927Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Cancer Therapeutics CRC
- Developer Bionomics; Cancer Therapeutics CRC
- Class Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Malignant melanoma; Solid tumours
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in Solid-tumours in Australia
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in Australia (PO, Tablet)
- 04 Nov 2017 No recent reports of development identified for research development in Breast-cancer in Australia